Food Demand Is Shifting

American dairy farmers are producing into a softer market at the same time a new class of weight-loss drugs is changing what some shoppers want to eat. In March, the United States Department of Agriculture said the 2026 dairy herd would average 9.57 million cows and milk production would reach 234.7 billion pounds, even as wholesale price forecasts for products like Cheddar and nonfat dry milk were being revised lower. (ers.usda.gov) (yankton.net) That is a hard setup for dairy because milk does not wait around like canned soup. When more milk shows up than buyers want for cheese, powder, or butter, processors have to clear it fast, and margins get squeezed. (ers.usda.gov) (yankton.net) Now add the drug side. Glucagon-like peptide-1 medicines such as semaglutide and tirzepatide slow digestion and reduce appetite, so people often eat less food overall and become pickier about what makes it onto the plate. (foxbaltimore.com) (news-medical.net) One recent supermarket study found that after people started these drugs, the nutritional quality of their grocery baskets improved and the share of minimally processed foods rose. The same study tied drug use to lower purchases of ultra-processed foods, which is exactly the kind of shift that can hit snack makers before it hits the farm gate. (jamanetwork.com) An agricultural economics paper presented this month found something more specific: households using these drugs spent about $11 to $13 more per week on food away from home, while showing stronger willingness to pay for protein products. That points demand toward smaller, denser, higher-protein meals rather than the old model of selling more volume. (aaea.org) That sounds like good news for dairy until you look closer. If shoppers want more protein, Greek yogurt, cottage cheese, and high-protein shakes can win, but plain milk, ice cream, and bulk cheese do not automatically win with them. (foxbaltimore.com) (aaea.org) Doctors and nutrition researchers are also flagging a second problem: eating less can slide into eating too little of the right things. A study released on April 9 found real-world users of these drugs showed widespread protein inadequacy, more meal skipping, and risks around fiber, iron, calcium, and several vitamins. (news-medical.net) (link.springer.com) That creates an unusual opening for food companies. If a person on semaglutide is eating fewer bites per day, every bite has to work harder, which makes foods marketed around protein, calcium, and satiety more valuable than foods built around size or indulgence alone. (link.springer.com) (foxbaltimore.com) The forecasting problem is that these two trends move in opposite directions. Dairy supply is still a tonnage business measured in billions of pounds, while drug-driven demand is becoming a precision business measured in protein grams, portion size, and who in the household is actually using the medicine. (ers.usda.gov) (aaea.org) So the next fight in food is not just over how much people eat. It is over whether farmers, processors, and retailers can pivot fast enough from selling more calories to selling the right calories before oversupply turns a milk glut into a pricing problem. (yankton.net) (foxbaltimore.com)